STAMFORD, Conn., August 1, 2023 – FDA has approved Harm Reduction Therapeutics’ (HRT) new drug application for RiVive™ (Naloxone HCl Nasal Spray 3 mg) to be available over the counter (OTC) for the emergency treatment of opioid overdose. Naloxone is an opioid...
Stamford, Conn. – Today, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s chapter 11 Plan of Reorganization (the “Plan”), affirming the bankruptcy court’s September 2021 confirmation order. “The Second Circuit’s ruling is a victory...
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection Stamford, Conn., March 28, 2023 – Purdue Pharma L.P. is accepting proposals for investigator-initiated research...
Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma $9 million in funding for commercial readiness approved by the Bankruptcy Court Harm Reduction Therapeutics’...
Stamford, Conn., Jan, 18, 2023 – Purdue Pharma L.P. (“Purdue”) announced that FDA has accepted and granted priority review to the company’s Abbreviated New Drug Application (ANDA) for Nalmefene Hydrochloride (HCl) injection, 2 mg/2 mL (1mg/1mL) Prefilled Syringe.*...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.